{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:25:26Z","timestamp":1792783526749,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Texas Christian University","id":[{"id":"https:\/\/ror.org\/054b0b564","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"DOI":"10.1007\/s40272-026-00779-w","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:51:28Z","timestamp":1790754688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exclusion by Design: Regulatory Reform and Evolving Frameworks for Clinical Trials in Pregnancy"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5546-429X","authenticated-orcid":false,"given":"Gregory L.","family":"Kearns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8056-8453","authenticated-orcid":false,"given":"Agnes","family":"Saint-Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"779_CR1","doi-asserted-by":"publisher","DOI":"10.17226\/27595","volume-title":"Advancing clinical research with pregnant and lactating populations: overcoming real and perceived liability risks","author":"National Academies of Sciences, Engineering, and Medicine","year":"2024","unstructured":"National Academies of Sciences, Engineering, and Medicine. Advancing clinical research with pregnant and lactating populations: overcoming real and perceived liability risks. The National Academies Press; 2024. https:\/\/doi.org\/10.17226\/27595."},{"key":"779_CR2","unstructured":"American College of Obstetricians and Gynecologists. https:\/\/www.acog.org\/store\/products\/patient-education\/pamphlets\/pregnancy\/nutrition-during-pregnancy. Accessed 29 Aug 2026."},{"issue":"1","key":"779_CR3","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1097\/AOG.0000000000002456","volume":"131","author":"American College of Obstetricians and Gynecologists","year":"2018","unstructured":"American College of Obstetricians and Gynecologists. Nausea and vomiting of pregnancy. ACOG Practice Bulletin No. 189. Obstet Gynecol. 2018;131(1):e15\u201330.","journal-title":"Obstet Gynecol"},{"issue":"23","key":"779_CR4","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1001\/jama.2018.18307","volume":"320","author":"KF Huybrechts","year":"2018","unstructured":"Huybrechts KF, Hern\u00e1ndez-D\u00edaz S, Straub L, Gray KJ, Zhu Y, Patorno E, et al. Association of maternal first-trimester ondansetron use with cardiac malformations and oral clefts in offspring. JAMA. 2018;320(23):2429\u201337. https:\/\/doi.org\/10.1001\/jama.2018.18307.","journal-title":"JAMA"},{"key":"779_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/s0889-8553(02)00065-1","volume":"32","author":"JE Richter","year":"2003","unstructured":"Richter JE. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am. 2003;32:235\u201361. https:\/\/doi.org\/10.1016\/s0889-8553(02)00065-1.","journal-title":"Gastroenterol Clin North Am"},{"issue":"2","key":"779_CR6","doi-asserted-by":"publisher","first-page":"178.e1","DOI":"10.1016\/j.ajog.2007.08.040","volume":"198","author":"C Rebordosa","year":"2008","unstructured":"Rebordosa C, Kogevinas M, Horvath-Puho E, Norgard B, Morales M, Czeizel AE, et al. Acetaminophen use during pregnancy: effects on risk for congenital abnormalities and other outcomes. Am J Obstet Gynecol. 2008;198(2):178.e1-7. https:\/\/doi.org\/10.1016\/j.ajog.2007.08.040.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"779_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ajog.2004.04.025","volume":"191","author":"SE Andrade","year":"2004","unstructured":"Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191(2):398\u2013407. https:\/\/doi.org\/10.1016\/j.ajog.2004.04.025.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"779_CR8","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","volume":"135","author":"American College of Obstetricians and Gynecologists","year":"2020","unstructured":"American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol. 2020;135(6):e237\u201360. https:\/\/doi.org\/10.1097\/AOG.0000000000003891.","journal-title":"Obstet Gynecol"},{"issue":"12","key":"779_CR9","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jama.2021.14781","volume":"326","author":"KW Davidson","year":"2021","unstructured":"US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, et al. Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(12):1186\u201391. https:\/\/doi.org\/10.1001\/jama.2021.14781.","journal-title":"JAMA"},{"key":"779_CR10","unstructured":"Centers for Disease Control and Prevention. National diabetes statistics report, 2020. https:\/\/diabetesresearch.org\/wp-content\/uploads\/2022\/05\/national-diabetes-statistics-report-2020.pdf. Accessed 29 Aug 2026."},{"issue":"3","key":"779_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/thy.2016.0457","volume":"27","author":"EK Alexander","year":"2017","unstructured":"Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27(3):315\u201389. https:\/\/doi.org\/10.1089\/thy.2016.0457.","journal-title":"Thyroid"},{"issue":"3","key":"779_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/AOG.0b013e3181ba0632","volume":"114","author":"KA Yonkers","year":"2009","unstructured":"Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, et al. Management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009;114(3):703\u201313. https:\/\/doi.org\/10.1097\/AOG.0b013e3181ba0632.","journal-title":"Obstet Gynecol"},{"issue":"2 suppl","key":"779_CR13","doi-asserted-by":"publisher","first-page":"e691S","DOI":"10.1378\/chest.11-2300","volume":"141","author":"SM Bates","year":"2012","unstructured":"Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e691S-e736S. https:\/\/doi.org\/10.1378\/chest.11-2300.","journal-title":"Chest"},{"key":"779_CR14","doi-asserted-by":"publisher","DOI":"10.5863\/JPPT-25-01217","author":"C Linardos","year":"2026","unstructured":"Linardos C, Whitney E, Schluterman H, Eletel L, Thomas T, Kearns GL. Off-label use of medicines in pediatrics: necessary and not \u201coff-knowledge.\u201d J Pediatr Pharmacol Ther. 2026. https:\/\/doi.org\/10.5863\/JPPT-25-01217. (ahead of print).","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"779_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.5863\/JPPT-26-00048","volume":"31","author":"CA Knoderer","year":"2026","unstructured":"Knoderer CA, Burk SB, Luedtke S, Reed MD. Beyond the headlines: examining the evidence around acetaminophen and autism risk. J Pediatr Pharmacol Ther. 2026;31(3):456\u201362. https:\/\/doi.org\/10.5863\/JPPT-26-00048.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"14","key":"779_CR16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jama.2024.3172","volume":"331","author":"VH Ahlqvist","year":"2024","unstructured":"Ahlqvist VH, Sj\u00f6qvist H, Dalman C, Karlsson H, Stephansson O, Johansson S, et al. Acetaminophen use during pregnancy and children\u2019s risk of autism, ADHD, and intellectual disability. JAMA. 2024;331(14):1205\u201314. https:\/\/doi.org\/10.1001\/jama.2024.3172.","journal-title":"JAMA"},{"issue":"3","key":"779_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.5863\/JPPT-26-X0111","volume":"31","author":"K Myers","year":"2026","unstructured":"Myers K, Kearns GL. Acetaminophen: a mother and child\u2019s friend turned foe. J Pediatr Pharmacol Ther. 2026;31(3):453\u20135. https:\/\/doi.org\/10.5863\/JPPT-26-X0111.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"7","key":"779_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/bdra.20277","volume":"76","author":"MJ Edwards","year":"2006","unstructured":"Edwards MJ. Hyperthermia and fever during pregnancy. Birth Defects Res A Clin Mol Teratol. 2006;76(7):507\u201316. https:\/\/doi.org\/10.1002\/bdra.20277.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"9345","key":"779_CR19","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/S0140-6736(02)11518-2","volume":"360","author":"AMN Andersen","year":"2002","unstructured":"Andersen AMN, Vastrup P, Wohlfahrt J, Andersen PK, Olsen J, Melbye M. Fever in pregnancy and risk of fetal death: a cohort study. Lancet. 2002;360(9345):1552\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(02)11518-2.","journal-title":"Lancet"},{"issue":"12","key":"779_CR20","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/bdr2.1696","volume":"112","author":"JM Graham Jr.","year":"2020","unstructured":"Graham JM Jr. Update on the gestational effects of maternal hyperthermia. Birth Defects Res. 2020;112(12):943\u201352. https:\/\/doi.org\/10.1002\/bdr2.1696.","journal-title":"Birth Defects Res"},{"key":"779_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-088141","volume":"391","author":"J Sheikh","year":"2025","unstructured":"Sheikh J, Allotey J, Sobhy S, Plana MN, Martinez-Barros H, Naidu H, et al. Maternal paracetamol (acetaminophen) use during pregnancy and risk of autism spectrum disorder and attention deficit\/hyperactivity disorder in offspring: umbrella review of systematic reviews. BMJ. 2025;391:e088141. https:\/\/doi.org\/10.1136\/bmj-2025-088141.","journal-title":"BMJ"},{"issue":"10","key":"779_CR22","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1161\/CIR.0000000000001206","volume":"149","author":"AS Batra","year":"2024","unstructured":"Batra AS, Silka MJ, Borquez A, Cuneo B, Dechert B, Jaeggi E, et al. Pharmacological management of cardiac arrhythmias in the fetal and neonatal periods: a scientific statement from the American Heart Association: endorsed by the Pediatric & Congenital Electrophysiology Society (PACES). Circulation. 2024;149(10):e937\u201352. https:\/\/doi.org\/10.1161\/CIR.0000000000001206.","journal-title":"Circulation"},{"issue":"23","key":"779_CR23","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1161\/01.cir.101.23.2721","volume":"101","author":"MA Oudijk","year":"2000","unstructured":"Oudijk MA, Michon MM, Kleinman CS, Kapusta L, Stoutenbeek P, Visser GH, et al. Sotalol in the treatment of fetal dysrhythmias. Circulation. 2000;101(23):2721\u20136. https:\/\/doi.org\/10.1161\/01.cir.101.23.2721.","journal-title":"Circulation"},{"issue":"4","key":"779_CR24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.clp.2007.10.002","volume":"34","author":"JF Strasburger","year":"2007","unstructured":"Strasburger JF, Cheulkar B, Wichman HJ. Perinatal arrhythmias: diagnosis and management. Clin Perinatol. 2007;34(4):627\u201352. https:\/\/doi.org\/10.1016\/j.clp.2007.10.002.","journal-title":"Clin Perinatol"},{"key":"779_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004454.pub3","volume":"3","author":"D Roberts","year":"2017","unstructured":"Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;3:CD004454. https:\/\/doi.org\/10.1002\/14651858.CD004454.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"779_CR26","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1097\/AOG.0000000000001267","volume":"127","author":"American College of Obstetricians and Gynecologists","year":"2016","unstructured":"American College of Obstetricians and Gynecologists. Committee Opinion No. 652: magnesium sulfate use in obstetrics. Obstet Gynecol. 2016;127(1):e52\u20133. https:\/\/doi.org\/10.1097\/AOG.0000000000001267.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"779_CR27","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-3860","volume":"139","author":"YA Maldonado","year":"2017","unstructured":"Maldonado YA, Read JS, Committee on Infectious Diseases. Diagnosis, treatment, and prevention of congenital toxoplasmosis in the United States. Pediatrics. 2017;139(2):e20163860. https:\/\/doi.org\/10.1542\/peds.2016-3860.","journal-title":"Pediatrics"},{"issue":"5","key":"779_CR28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/pd.59","volume":"21","author":"M Enders","year":"2001","unstructured":"Enders M, Bader U, Lindeman L, Schalasta G, Daiminger A. Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome. Prenat Diagn. 2001;21(5):362\u201377. https:\/\/doi.org\/10.1002\/pd.59.","journal-title":"Prenat Diagn"},{"key":"779_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000363152","volume":"26","author":"M Polak","year":"2014","unstructured":"Polak M. Human fetal thyroid function. Endocr Dev. 2014;26:17\u201325. https:\/\/doi.org\/10.1159\/000363152.","journal-title":"Endocr Dev"},{"issue":"2","key":"779_CR30","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.clp.2009.03.008","volume":"36","author":"S Hirose","year":"2009","unstructured":"Hirose S, Farmer DL. Fetal surgery for myelomeningocele. Clin Perinatol. 2009;36(2):431\u20138. https:\/\/doi.org\/10.1016\/j.clp.2009.03.008.","journal-title":"Clin Perinatol"},{"issue":"3","key":"779_CR31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/ajmg.c.32135","volume":"199","author":"TR Kolarova","year":"2025","unstructured":"Kolarova TR, Cheng E. In utero therapies, the next frontier. Am J Med Genet C Semin Med Genet. 2025;199(3):194\u2013202. https:\/\/doi.org\/10.1002\/ajmg.c.32135.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"779_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2024.102542","author":"R Sagar","year":"2024","unstructured":"Sagar R, David AL. Fetal therapies (stem cell transplantation; enzyme replacement therapy; in utero genetic therapies). Best Pract Res Clin Obstet Gynaecol. 2024. https:\/\/doi.org\/10.1016\/j.bpobgyn.2024.102542.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"1","key":"779_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/genes14010153","volume":"14","author":"H Schneider","year":"2023","unstructured":"Schneider H, Hadj-Rabia S, Faschingbauer F, Bodemer C, Grange DK, Norton ME, et al. Protocol for the phase 2 EDELIFE trial investigating the efficacy and safety of Intra-Amniotic ER004 administration to male subjects with X-linked hypohidrotic ectodermal dysplasia. Genes (Basel). 2023;14(1):153. https:\/\/doi.org\/10.3390\/genes14010153.","journal-title":"Genes (Basel)"},{"issue":"13","key":"779_CR34","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/pd.6460","volume":"43","author":"A Herzeg","year":"2023","unstructured":"Herzeg A, Borges B, Lianoglou BR, Gonzalez-Velez J, Canepa E, Munar D, et al. Intrauterine enzyme replacement therapies for lysosomal storage disorders: current developments and promising future prospects. Prenat Diagn. 2023;43(13):1638\u201349. https:\/\/doi.org\/10.1002\/pd.6460.","journal-title":"Prenat Diagn"},{"issue":"6","key":"779_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-079767","volume":"14","author":"RL Sagar","year":"2024","unstructured":"Sagar RL, \u00c5str\u00f6m E, Chitty LS, Crowe B, David AL, DeVile C, et al. An exploratory open-label multicentre phase I\/II trial evaluating the safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe osteogenesis imperfecta in infants and fetuses: the BOOSTB4 trial protocol. BMJ Open. 2024;14(6):e079767. https:\/\/doi.org\/10.1136\/bmjopen-2023-079767.","journal-title":"BMJ Open"},{"issue":"6","key":"779_CR36","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s43441-022-00433-w","volume":"56","author":"AL David","year":"2022","unstructured":"David AL, Ahmadzia H, Ashcroft R, Bucci-Rechtweg C, Spencer RN, Thornton S. Improving development of drug treatments for pregnant women and the fetus. Ther Innov Regul Sci. 2022;56(6):976\u201390. https:\/\/doi.org\/10.1007\/s43441-022-00433-w.","journal-title":"Ther Innov Regul Sci"},{"issue":"6","key":"779_CR37","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ajog.2022.07.037","volume":"227","author":"CA Sewell","year":"2022","unstructured":"Sewell CA, Sheehan SM, Gill MS, Henry LM, Bucci-Rechtweg C, Gyamfi-Bannerman C, et al. Scientific, ethical, and legal considerations for the inclusion of pregnant people in clinical trials. Am J Obstet Gynecol. 2022;227(6):805\u201311. https:\/\/doi.org\/10.1016\/j.ajog.2022.07.037.","journal-title":"Am J Obstet Gynecol"},{"key":"779_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.semperi.2025.152073","volume":"49","author":"CL Pratt","year":"2025","unstructured":"Pratt CL, Hahn NM. Review of pharmacology of medications during pregnancy. Semin Perinatol. 2025;49:152073. https:\/\/doi.org\/10.1016\/j.semperi.2025.152073.","journal-title":"Semin Perinatol"},{"key":"779_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1146\/annurev-pharmtox-011613-140009","volume":"54","author":"AB Ke","year":"2014","unstructured":"Ke AB, Rostami-Hodjegan A, Zhao P, Unadkat JD. Pharmacometrics in pregnancy. Annu Rev Pharmacol Toxicol. 2014;54:53\u201369. https:\/\/doi.org\/10.1146\/annurev-pharmtox-011613-140009.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"779_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.733823","volume":"9","author":"N Chaphekar","year":"2021","unstructured":"Chaphekar N, Dodeja P, Shaik IH, Caritis S, Venkataramanan R. Maternal\u2013fetal pharmacology of drugs: a review of current status of the application of physiologically based pharmacokinetic models. Front Pediatr. 2021;9:733823. https:\/\/doi.org\/10.3389\/fped.2021.733823.","journal-title":"Front Pediatr"},{"issue":"11","key":"779_CR41","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/psp4.13267","volume":"13","author":"AC Eke","year":"2024","unstructured":"Eke AC, Adams E, Eleje GU, Ezebialu IU, Aliyu MH. Pharmacometrics in obstetrics and maternal\u2013fetal medicine research: bridging gaps in maternal and fetal pharmacology. CPT Pharmacometr Syst Pharmacol. 2024;13(11):1835\u201340. https:\/\/doi.org\/10.1002\/psp4.13267.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"3","key":"779_CR42","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/fcp.12967","volume":"38","author":"M Berezowska","year":"2024","unstructured":"Berezowska M, Sharma P, Pilla Reddy V, Coppola P. Physiologically based pharmacokinetic modeling of drugs in pregnancy: a mini-review on availability and limitations. Fundam Clin Pharmacol. 2024;38(3):402\u20139. https:\/\/doi.org\/10.1111\/fcp.12967.","journal-title":"Fundam Clin Pharmacol"},{"issue":"8","key":"779_CR43","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1124\/dmd.117.075192","volume":"45","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Imperial MZ, Patilea-Vrana GI, Wedagedera J, Gaohua L, Unadkat JD. Development of a novel maternal\u2013fetal physiologically based pharmacokinetic model I: insights into factors that determine fetal drug exposure through simulations and sensitivity analyses. Drug Metab Dispos. 2017;45(8):920\u201338. https:\/\/doi.org\/10.1124\/dmd.117.075192.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"779_CR44","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s43441-024-00736-0","volume":"59","author":"A Alexe","year":"2025","unstructured":"Alexe A, Wurst K, Balramsingh-Harry L, Apara O, Abramova N, Eisele O, et al. Points to consider on the use of medicines in pregnancy throughout the product lifecycle based on global regulatory guidance. Ther Innov Regul Sci. 2025;59(3):462\u201370. https:\/\/doi.org\/10.1007\/s43441-024-00736-0.","journal-title":"Ther Innov Regul Sci"},{"key":"779_CR45","unstructured":"21st Century Cures Act. US Food and Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/21st-century-cures-act\/21st-century-cures-act-deliverables. Accessed 17 May 2026."},{"key":"779_CR46","unstructured":"Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC). Eunice Kennedy Shriver National Institute of Child Health and Human Development. https:\/\/www.nichd.nih.gov\/about\/advisory\/PRGLAC. Accessed 17 May 2026."},{"key":"779_CR47","unstructured":"2024 PRGLAC progress report. Eunice Kennedy Shriver National Institute of Child Health and Human Development. https:\/\/www.nichd.nih.gov\/sites\/default\/files\/inline-files\/PRGLAC_Progress_Report.pdf. Accessed 17 May 2026."},{"issue":"6","key":"779_CR48","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.whi.2022.06.004","volume":"32","author":"KM Kons","year":"2022","unstructured":"Kons KM, Wood ML, Peck LC, Hershberger SM, Kunselman AR, Stetter C, et al. Exclusion of reproductive-aged women in COVID-19 vaccination and clinical trials. Womens Health Issues. 2022;32(6):557\u201363. https:\/\/doi.org\/10.1016\/j.whi.2022.06.004.","journal-title":"Womens Health Issues"},{"key":"779_CR49","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1056\/NEJMoa2104983","volume":"384","author":"TT Shimabukuro","year":"2021","unstructured":"Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagyotakopoulos L, et al. Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons. N Engl J Med. 2021;384:2273\u201382.","journal-title":"N Engl J Med"},{"issue":"4","key":"779_CR50","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/cpt.2212","volume":"110","author":"J Nooney","year":"2021","unstructured":"Nooney J, Thor S, de Vries C, Clements J, Sahin L, Hua W, et al. Assuring access to safe medicines in pregnancy and breastfeeding. Clin Pharmacol Ther. 2021;110(4):941\u20135. https:\/\/doi.org\/10.1002\/cpt.2212.","journal-title":"Clin Pharmacol Ther"},{"key":"779_CR51","unstructured":"Safer medicines in pregnancy and breastfeeding consortium. UK Government. https:\/\/www.gov.uk\/government\/publications\/safer-medicines-in-pregnancy-and-breastfeeding-consortium. Accessed 17 May 2026."},{"issue":"1","key":"779_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cpt.378","volume":"100","author":"A Saint-Raymond","year":"2016","unstructured":"Saint-Raymond A, de Vries C. Medicine safety in pregnancy and ambitions for the EU medicine regulatory framework. Clin Pharmacol Ther. 2016;100(1):21\u20133. https:\/\/doi.org\/10.1002\/cpt.378.","journal-title":"Clin Pharmacol Ther"},{"key":"779_CR53","unstructured":"EMA regulatory science strategy 2025. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/about-us\/how-we-work\/regulatory-science-strategy. Accessed 17 May 2026."},{"key":"779_CR54","unstructured":"EMA Medicines during pregnancy and breastfeeding strategy. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/medicines-during-pregnancy-breastfeeding. Accessed 17 May 2026."},{"key":"779_CR55","unstructured":"EMA Good Pharmacovigilance Practice. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-final-considerations-pregnant-breastfeeding-women-their-children-exposed-utero-or-breastmilk_en.pdf. Accessed 25 Aug 2026."},{"key":"779_CR56","unstructured":"IMI Conception Project. https:\/\/www.imi-conception.eu\/. Accessed 25 Aug 2026."},{"key":"779_CR57","unstructured":"EMA Product information QRD templates for human medicines. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/product-information-requirements\/product-information-qrd-templates-human. Accessed 17 May 2026."},{"key":"779_CR58","unstructured":"EMA workshop on pregnancy and lactation. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/events\/workshop-benefit-risk-medicines-used-during-pregnancy-breastfeeding. Accessed 17 May 2026."},{"key":"779_CR59","unstructured":"International Coalition of Medicines Regulatory Authorities (ICMRA) COVID-19 statement. https:\/\/icmra.info\/drupal\/en\/covid-19\/9february2021. Accessed 17 May 2026."},{"key":"779_CR60","unstructured":"ICH harmonized guideline E21. International Council for Harmonization. https:\/\/www.ich.org\/page\/efficacy-guidelines. Accessed 17 May 2026."},{"key":"779_CR61","unstructured":"ICH harmonized guideline S5(R4): detection of toxicity to reproduction for human pharmaceuticals. International Council for Harmonization. https:\/\/www.ich.org\/page\/safety-guidelines. Accessed 17 May 2026."},{"key":"779_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(25)00069-5","author":"ML Costa","year":"2025","unstructured":"Costa ML, Cecatti JG. Urgent and decisive action needed in maternal morbidity and mortality to prevent stagnation in progress. Lancet Glob Health. 2025. https:\/\/doi.org\/10.1016\/S2214-109X(25)00069-5.","journal-title":"Lancet Glob Health"},{"key":"779_CR63","doi-asserted-by":"publisher","first-page":"e740","DOI":"10.1016\/S2214-109X(24)00512-6","volume":"13","author":"T Dey","year":"2025","unstructured":"Dey T, Widmer M, Coomarasamy A, Goudar SS, Berrueta M, Coutinho E, et al. Advancing maternal and perinatal health through clinical trials: key insights from a WHO global consultation. Lancet Glob Health. 2025;13:e740\u20138.","journal-title":"Lancet Glob Health"},{"key":"779_CR64","unstructured":"AMA-AUDA-NEPAD medical priority products report. https:\/\/au-ama.africa\/wp-content\/uploads\/2025\/12\/24-Medical-Priority-Products-Report_1.pdf. Accessed 17 May 2026."},{"key":"779_CR65","unstructured":"Sahin L. FDA updates presentation. Presented November 2023. https:\/\/www.nichd.nih.gov\/sites\/default\/files\/inline-files\/PRGLAC_2023_Nov_Sahin_FDA_updates.pdf. Accessed 17 May 2026."},{"key":"779_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2025.109035","volume":"137","author":"N Powles-Glover","year":"2025","unstructured":"Powles-Glover N, Kaczor AR, Van Cruchten S, Bowman CJ, Brannen KC, Demarta-Gatsi C, et al. New approach methodologies for assessing developmental toxicity of pharmaceuticals: case examples and future directions. Reprod Toxicol. 2025;137:109035. https:\/\/doi.org\/10.1016\/j.reprotox.2025.109035.","journal-title":"Reprod Toxicol"},{"key":"779_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110114","volume":"127","author":"S Gao","year":"2020","unstructured":"Gao S, Wang S, Fan R, Hu J. Recent advances in the molecular mechanism of thalidomide teratogenicity. Biomed Pharmacother. 2020;127:110114. https:\/\/doi.org\/10.1016\/j.biopha.2020.110114.","journal-title":"Biomed Pharmacother"},{"key":"779_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2025.1688641","volume":"7","author":"K De Clercq","year":"2026","unstructured":"De Clercq K, Velazquez C, Persoons E, Wolters V, Van de Ven M, Amant F. Evaluating chemotherapy-driven placental alterations and their impact on fetal development. Front Toxicol. 2026;7:1688641. https:\/\/doi.org\/10.3389\/ftox.2025.1688641.","journal-title":"Front Toxicol"},{"key":"779_CR69","doi-asserted-by":"publisher","unstructured":"Kruse AM, Huis In 't Veld EA, van Grotel M,\u00a0Amant F, van Tinteren H, van den Heuvel-Eibrink MM et al. Motor development in toddlers prenatally exposed to maternal cancer treatment: a national cohort study in the Netherlands. EClinicalMedicine. 2026;92:103738. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103738.","DOI":"10.1016\/j.eclinm.2025.103738"},{"key":"779_CR70","unstructured":"Amant F. Chemotherapy during pregnancy. 2015. https:\/\/motherhoodcollectiveimpact.org\/a-decade-of-cancer-and-pregnancy\/. Accessed 17 May 2026."},{"key":"779_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s41021-015-0001-0","volume":"37","author":"A Takei","year":"2015","unstructured":"Takei A. ILSI Health and Environmental Sciences Institute (HESI), global leader in advancing translational science to create science-based solutions for a sustainable, healthier world. Genes Environ. 2015;37:1. https:\/\/doi.org\/10.1186\/s41021-015-0001-0.","journal-title":"Genes Environ"},{"issue":"1","key":"779_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12910-024-01055-7","volume":"25","author":"A Ssali","year":"2024","unstructured":"Ssali A, Namugumya R, Nalubega P, Kyohere M, Seeley J, Le Doare K. Exploring the consent process among pregnant and breastfeeding women taking part in a maternal vaccine clinical trial in Kampala, Uganda: a qualitative study. BMC Med Ethics. 2024;25(1):57. https:\/\/doi.org\/10.1186\/s12910-024-01055-7.","journal-title":"BMC Med Ethics"},{"key":"779_CR73","unstructured":"World Medical Association Declaration of Helsinki. World Medical Association. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki\/. Accessed 17 May 2026."},{"key":"779_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-025-02274-6","volume":"18","author":"EM Meslin","year":"2025","unstructured":"Meslin EM, Kant C, Mazzuri S, Knoppers BM. Prenatal therapies: a points to consider framework for responsible innovation. BMC Med Genom. 2025;18:191. https:\/\/doi.org\/10.1186\/s12920-025-02274-6.","journal-title":"BMC Med Genom"},{"key":"779_CR75","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.18.0065","author":"AA Westin","year":"2018","unstructured":"Westin AA, Reimers A, Spigset O. Should pregnant women receive lower or higher medication doses? Tidsskr Nor Laegeforen. 2018. https:\/\/doi.org\/10.4045\/tidsskr.18.0065.","journal-title":"Tidsskr Nor Laegeforen"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00779-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00779-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00779-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:03:35Z","timestamp":1790798615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00779-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":75,"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00779-w","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Drs Kearns and Saint-Raymond contributed equally to the writing, reviewing, and editing of the manuscript. Both authors have read and approved the final version of the manuscript, and agree to be accountable for the work.","order":1,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gregory Kearns is an Editorial Board member of Pediatric Drugs. Dr Kearns was not involved in the selection of peer reviewers for the manuscript or in any subsequent editorial decisions. Agnes Saint-Raymond has no conflicts to disclose. The views expressed in this article are those\u00a0of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of Concept Foundation.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The content of this article does not require EC\/IRB review.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data and materials were submitted to Pediatric Drugs.","order":6,"name":"Ethics","label":"Availability of data and materials (data transparency)","group":{"name":"EthicsHeading","label":"Declarations"}}]}}